Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from WisdomTree India Earnings Fund ( (EPI) ).
ESSA Pharma Inc. has amended its Business Combination Agreement with XenoTherapeutics Inc., a non-profit biotechnology company, to adjust the financial terms for its shareholders. The revised agreement includes a cash payment of approximately $0.12 per share and a contingent value right (CVR) of up to $0.14 per share, reflecting potential liabilities and updated cash balance estimates. The special meeting to approve the amended terms has been rescheduled to October 3, 2025, allowing shareholders more time to consider the changes.
Spark’s Take on EPI Stock
According to Spark, TipRanks’ AI Analyst, EPI is a Neutral.
ESSA Pharma’s overall score reflects significant financial challenges with no revenue and ongoing losses. Technical indicators provide some positive signals, but caution is advised due to potential overbought conditions. The negative P/E ratio and lack of dividends further underline investment risks.
To see Spark’s full report on EPI stock, click here.
More about WisdomTree India Earnings Fund
ESSA Pharma Inc. is a pharmaceutical company that was previously focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Average Trading Volume: 791,993
Current Market Cap: $2.91B
See more data about EPI stock on TipRanks’ Stock Analysis page.